Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13448038 | 0.84 | KMT2A (0.58) | MAPTALDH1A1TDP1KMT2ALMNA | |
| SCHEMBL768486 | 0.84 | KMT2A (0.57) | MAPTALDH1A1TDP1KMT2ALMNA | |
| SCHEMBL12157882 | 0.83 | PLOD2 (0.44) | MAPTALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL4096578 | 0.83 | LMNA (0.59) | MAPTALDH1A1L3MBTL1KMT2ALMNA | |
| SCHEMBL17521946 | 0.83 | ALDH1A1 (0.43) | NR4A2MAPTALDH1A1TDP1L3MBTL1 | |
| SCHEMBL13304061 | 0.81 | MMP1 (0.58) | MAPTALDH1A1TDP1L3MBTL1KMT2A | |
| SCHEMBL4181717 | 0.81 | MAPT (0.50) | NR4A2MAPTALDH1A1TDP1L3MBTL1 | |
| SCHEMBL17884960 | 0.81 | PLOD2 (0.50) | ALDH1A1TDP1L3MBTL1KMT2ALMNA | |
| SCHEMBL29835154 | 0.81 | PLOD2 (0.50) | ALDH1A1TDP1L3MBTL1KMT2ALMNA | |
| SCHEMBL19283953 | 0.80 | LOXL2 (0.47) | ALDH1A1HPGDPOLBCTNNB1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| US-9926281-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2018-03-27 | — | — | US | disclosed |
| US-20180002293-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2018-01-04 | — | — | US | disclosed |
| US-8034961-B2 | Reduction of 4-aryl-4-ketobutanoic acid derivatives utilizing ruthenium containing catalysts | LANXESS DEUTSCHLAND GMBH (US) | 2011-10-11 | — | — | US | disclosed |
| US-20080103316-A1 | Process for stereoselectively reducing 4-ARYL-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-05-01 | — | — | US | disclosed |
| US-7329766-B2 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2008-02-12 | — | — | US | disclosed |
| US-20050245760-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| US-6921822-B2 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-26 | — | — | US | disclosed |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1369410-A1 | Process for the stereoselective reduction of derivatives of 4-aryl-4-oxobutyric acid | BAYER AG (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-6028224-A | Fluoxetine process from benzoylpropionic acid | SEPRACOR INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999067196-A1 | FLUOXETINE PROCESS FROM BENZOYLPROPIONIC ACID | SEPRACOR INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5936124-A | Fluoxetine process from benzoylpropionic acid | SEPACOR INC. (US) | 1999-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103316-A1 | Process for stereoselectively reducing 4-ARYL-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NR4A2 188/4885MAPT 4303/4885ALDH1A1 133/4885 |
| US-20180002293-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | ADAMTS1, ADAMTS5, ADAMTS7 | NR4A2 2820/4885MAPT 3433/4885ALDH1A1 441/4885 |
| US-20040030181-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NR4A2 188/4885MAPT 4303/4885ALDH1A1 133/4885 |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | NR4A2 2820/4885MAPT 3433/4885ALDH1A1 441/4885 |
| US-20050245760-A1 | Process for stereoselectively reducing 4-aryl-4-oxobutanoic acid derivatives | HPD, GRHPR, CYP4B1 | NR4A2 188/4885MAPT 4303/4885ALDH1A1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.